The genomic landscape of PCa has been well-defined, with alterations, such as the TMPRSS2:ERG fusion (Tomlins et al., 2005; Taylor et al., 2010); SPOP mutations (Barbieri et al., 2012; Abeshouse et al., 2015); and the losses of NKX3-1 (Emmert-Buck et al., 1995; Abdulkadir et al., 2002), CHD1 (Augello et al., 2019), MAP3K7 (Wu et al., 2012), and PTEN (Cairns et al., 1997; Wang et al., 2003), playing a role in disease development but none sufficient to drive PCa in men to become metastatic. This evidence concerns the gene MAP3K7 and posterior cortical atrophy.